VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)
$102.8123 -0.5277 (-0.5106%)
Analysed VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) News Sources
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
02-04-2026
yahoo.com
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
30-03-2026
yahoo.com
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
28-03-2026
247wallst.com
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
23-03-2026
yahoo.com
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
04-02-2026
yahoo.com
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
23-01-2026
247wallst.com
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
02-01-2026
yahoo.com
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
29-12-2025
yahoo.com
Pharma's $370B Bet on America: The ETF Plays for 2026
19-12-2025
yahoo.com
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
09-12-2025
yahoo.com
What is the current price of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)?
The current price of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) is $102.8123.
VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) absolute price change since previous trading day?
The absolute price change of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) since the previous trading day is $-0.5277.
VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) percentage price change since previous trading day?
The percentage price change of VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) since the previous trading day is -0.5106%.
What is the most recent average sentiment score for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)?
The most recent average sentiment score for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)?
The most recent sentiment for VANECK PHARMACEUTICAL ETF (PPH:NASDAQ) is .
SEC-8K** Filing Available For VANECK PHARMACEUTICAL ETF (PPH:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.